Pepgen inc. announces fda has lifted the clinical hold on its investigational new drug application for freedom-dm1 phase 1 study of pgn-edodm1 for myotonic dystrophy type 1 (dm1)

– lifting of fda hold allows freedom-dm1 study to launch in the u.s. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –

PEPG Ratings Summary

PEPG Quant Ranking